این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
پنجشنبه 7 آبان 1405
Middle East Journal of Cancer
، جلد ۱، شماره ۳، صفحات ۱۰۹-۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
Evaluation of Intravenous Magnesium Supplementation as Prophylaxis for Cisplatin-induced Hypomagnesemia
چکیده انگلیسی مقاله
Background : We assessed the effects of cisplatin-based chemotherapy, magnesium supplementation, probable contributory factors such as cisplatin cumulative dose and dose per cycle on serum magnesium levels. Methods : In this prospective randomized study, serum magnesium levels of 59 newly diagnosed adult patients receiving cisplatin-based chemotherapy were studied. The patients were randomly allocated to receive magnesium supplementation at a dose of 5 g IV per cycle (n=31) or to a control group (n=28). Serum magnesium levels < 1.8 mg/dL were considered to indicate hypomagnesemia. Results : The decrease in mean magnesium levels with continuing chemotherapy courses was significant in both groups with a more prominent decrease in the control group. In courses 4 and 5, mean magnesium levels were significantly higher among those who received magnesium supplementation than in the control group. Thirty patients (50.8%) had at least one incident of hypomagnesemia after beginning chemotherapy. All hypomagnesemia incidents were mild (mean 1.69, range; 1.52-1.79 mg/dL). Hypomagnesemia was more frequent in the control group (38.7% vs. 60.7%, P=0.09). Although age and sex had no significant effect on the incidence of hypomagnesemia, more hypomagnesemia incidents were observed in patients who received cisplatin in a single loading dose than in those who received the drug in divided doses for each cycle (71.4% % vs. 42.9%, P=0.056). Conclusion : Magnesium supplementation at a dose of 5 g per cycle partially compensated for cisplatin- induced magnesium loss. Monitoring magnesium levels and magnesium supplementation is warranted, especially for those undergoing protracted courses of cisplatin-based chemotherapy. Patients who receive the drug in a single loading dose might be more prone to magnesium loss.
کلیدواژههای انگلیسی مقاله
نویسندگان مقاله
کاظم انوری | kazem anvari
department of radiotherapy and oncology, cancer research center, omid hospital, mashhad university of medical sciences, mashhad, iran
سازمان اصلی تایید شده
: دانشگاه علوم پزشکی مشهد (Mashhad university of medical sciences)
مهدی sielanian طوسی | mehdi sielanian toussi
department of radiotherapy and oncology, cancer research center, omid hospital, mashhad university of medical sciences, mashhad, iran
سازمان اصلی تایید شده
: دانشگاه علوم پزشکی مشهد (Mashhad university of medical sciences)
مرجانه میرصدرایی | marjaneh mirsadraee
department of radiotherapy and oncology, cancer research center, omid hospital, mashhad university of medical sciences, mashhad, iran
سازمان اصلی تایید شده
: دانشگاه علوم پزشکی مشهد (Mashhad university of medical sciences)
نشانی اینترنتی
http://mejc.sums.ac.ir/index.php/mejc/article/view/87
فایل مقاله
فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
Original Article
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات